|
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). |
| |
|
Research Funding - Exact Sciences (Inst) |
| |
|
Consulting or Advisory Role - Genzyme |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Baylis Medical |
| |
|
Research Funding - Exact Sciences (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Research Funding - Genomic Health International |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca (I) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Leadership - Multiwave Technologies |
Consulting or Advisory Role - L'Oreal |
Speakers' Bureau - Pfizer |
Research Funding - Novartis; Roche Canada |
| |
|
Honoraria - Abbvie; Verity Pharmaceuticals |
| |
|
Employment - Roche Canada (I) |
Stock and Other Ownership Interests - Roche Canada (I) |
Honoraria - AstraZeneca; AstraZeneca |
Consulting or Advisory Role - Merck; Profound Medical; Takeda |
| |
|
No Relationships to Disclose |